Chemocentryx (CCXI) Return on Assets ROA from the second quarter of 2026 to second quarter of 2021 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Chemocentryx Inc.  (NASDAQ: CCXI)


Chemocentryx's ROA from the second quarter of 2026 to the second quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Chemocentryx's ROA in the second quarter of 2026?
Chemocentryx Inc. achieved a return on average assets (ROA) of 52.98 % in its second quarter of 2026, this is above CCXI's average return on assets of -25.28%.
Chemocentryx Inc. assets over the 12 months ending in its second quarter of 2026 are valued at $414 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 573 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 4640 to 4646.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Total Assets Change 1.27 % 4.18 % -8.47 % -15.2 % -16.38 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 219 309 -133 -141 -132
Return On Assets (TTM) 52.98 % 75.07 % -32.62 % -33.68 % -30.26 %
CCXI's Total Ranking # 4646 # 4640 # 4876 # 3967 # 3989
Total Assets (TTM) in million 423 419 416 397 417
Seq. Total Assets Change 0.84 % 0.77 % 4.87 % -4.98 % 3.74 %
Seq. Net Income Change - - - - -

CCXI's 5 Years Annual ROA >> Back to CCXI Management Effectiveness >> Compare CCXI ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 228
Sector # 574
Overall # 4536

Return On Assets Statistics
High Average Low
11.71 %
-25.28 %
-61.44 %
(Dec 31 2017)   (Mar 31 2016)





Financial Statements
Chemocentryx's Assets $ 423 million CCXI's Balance sheet
Chemocentryx's Income $ -131 million Quarterly CCXI's Income Statement
CCXI's Income by Division See CCXI's Income by Division



Annual Return On Assets (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018		 (Dec 31 2017)
FY 2017
Y / Y Total Assets Change -58.28 % 361.18 % 14.06 % -3.18 % -53.71 %
Total Assets in million 402 964 209 183 189
Y / Y Net Income Change - - - - -
Net Income in million -132 -55 -55 -38 18
Annual Return On Assets -32.75 % -5.74 % -26.54 % -20.71 % 9.43 %

CCXI's 5 Years Annual ROA >> Back to CCXI Management Effectiveness >> Compare CCXI ROA to its Competitors



More Return On Assets Ratios
CCXI's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CCXI's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CCXI's Competitors
Subscribers only: Roa for Chemocentryx's Suppliers
Subscribers only: Return On Assets for CCXI's Customers

You may also want to know
CCXI's Roi CCXI's Inventory Turnover Ratio CCXI's Growth Rates CCXI's Dividend Comparisons
CCXI's Profitability Ratios CCXI's Asset Turnover Ratio CCXI's Dividend Growth
CCXI's Roe CCXI's Valuation Ratios CCXI's Financial Strength Ratios CCXI's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Capforce Inc   141.40 %
Protagenic Therapeutics Inc new  137.58 %
Elutia Inc   108.72 %
Silexion Therapeutics Corp  99.09 %
Arbutus Biopharma Corp  96.04 %
Pulmatrix Inc   94.81 %
Quince Therapeutics Inc   88.46 %
Interpace Biosciences Inc   85.91 %
Oncotelic Therapeutics Inc   81.75 %
Rigel Pharmaceuticals Inc  72.27 %
Actinium Pharmaceuticals Inc  71.73 %
Sanuwave Health Inc   71.60 %
Exelixis Inc   70.51 %
Rallybio Corporation  64.51 %
Oramed Pharmaceuticals Inc  64.18 %
Fortress Biotech Inc   60.88 %
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %

Date modified: 2026-09-26T07:44:45+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.